EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Enhancing Fc ‐mediated effector functions of monoclonal antibodies: The example of HexaBodies

Hilma J van der Horst, Tuna Mutis iD

Immunological Reviews · 2024

DOI: 10.1111/imr.13394 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunological Reviews, 2024. Verfasst von Hilma J van der Horst und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU Medical Center, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Antibody-Dependent Cell Cytotoxicity, Immunoglobulin Fc Fragments, Antibodies, Monoclonal. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the approval of the CD20‐targeting monoclonal antibody (mAb) rituximab for the treatment of lymphoma in 1997, mAb therapy has significantly transformed cancer treatment. With over 90 FDA‐approved mAbs for the treatment of various hematological and solid cancers, modern cancer treatment relies heavily on these therapies. The overwhelming success of mAbs as cancer therapeutics is attributed to their broad applicability, high safety profile, and precise targeting of cancer‐associated surface antigens. Furthermore, mAbs can induce various anti‐tumor cytotoxic effector mechanisms including antibody‐dependent cellular cytotoxicity (ADCC), antibody‐dependent cellular phagocytosis (ADCP), and complement‐dependent cytotoxicity (CDC), all of which are mediated via their fragment crystallizable (Fc) domain. Over the past decades, these effector mechanisms have been substantially improved through Fc domain engineering. In this review, we will outline the different approaches to enhance Fc effector functions via Fc engineering of mAbs, with a specific emphasis on the so‐called “HexaBody” technology, which is designed to enhance the hexamerization of mAbs on the target cell surface, thereby inducing greater complement activation, CDC, and receptor clustering. The review will summarize the development, preclinical, and clinical testing of several HexaBodies designed for the treatment of B‐cell malignancies, as well as the potential use of the HexaBody technology beyond Fc‐mediated effector functions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibody-Dependent Cell CytotoxicityImmunoglobulin Fc FragmentsAntibodies, MonoclonalHumansAnimalsNeoplasmsPhagocytosisComplement ActivationProtein EngineeringAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

B‐cell malignanciesFc‐engineeringHexaBody technologyantibody therapycomplement‐mediated cytotoxicitymultiple myeloma

Substanzen

Immunoglobulin Fc FragmentsAntibodies, MonoclonalAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU Medical Center, Amsterdam, The Netherlands.

ORCID-Profile: Tuna Mutis

Zitieren

APA

van der Horst, H. J., & Mutis, T. (2024). Enhancing Fc ‐mediated effector functions of monoclonal antibodies: The example of HexaBodies. Immunological Reviews. https://doi.org/10.1111/imr.13394

Vancouver

van der Horst HJ, Mutis T. Enhancing Fc ‐mediated effector functions of monoclonal antibodies: The example of HexaBodies. Immunological Reviews. 2024. doi:10.1111/imr.13394

BibTeX
@article{vanderHorst2024,
  author = {van der Horst, Hilma J and Mutis, Tuna},
  title = {Enhancing Fc ‐mediated effector functions of monoclonal antibodies: The example of HexaBodies},
  journal = {Immunological Reviews},
  year = {2024},
  doi = {10.1111/imr.13394}
}
Kostenlos starten →